Retail Investors Hold Majority Stake in XBiotech Inc. (NASDAQ:XBIT), with 52% Ownership

XBiotech Inc. (NASDAQ:XBIT) has a significant control by retail investors with a 52% stake, while insiders hold 36% of the company. A total of 25 investors have a majority stake in the company, with a combined ownership of 47%. The ownership structure implies that retail investors have more power to influence management and governance-related decisions.

XBiotech Inc. (NASDAQ:XBIT) has experienced a notable increase in its stock price, crossing above its 50-day moving average during trading on August 20, 2025. The stock traded at a peak of $3.27, with a last traded price of $3.21. This upward movement indicates potential positive momentum for the biopharmaceutical company [1].

The company's market capitalization stands at $97.87 million, with institutional investors holding 55.70% of its stock. Several large entities, including Northern Trust Corp, Charles Schwab Investment Management Inc., and RBF Capital LLC, have recently increased their stakes in XBiotech, reflecting growing interest in the company [1].

XBiotech reported an earnings per share (EPS) of ($0.06) for the last quarter, indicating a loss. Despite this, the stock's performance suggests that investors are optimistic about the company's future prospects. The stock's 50-day moving average is $2.91, and its 200-day moving average is $3.02, providing a context for the recent price movement [1].

The ownership structure of XBiotech is significant, with retail investors holding 52% of the company's shares and insiders holding 36%. A total of 25 investors have a majority stake, with a combined ownership of 47%. This distribution of ownership implies that retail investors have more power to influence management and governance-related decisions [1].

While XBiotech currently has a Hold rating among analysts, top-rated analysts believe there are better buys available. MarketBeat has identified five stocks that top analysts are recommending to their clients, and XBiotech is not on the list [1].

For investors considering XBiotech, it is crucial to assess the company's fundamentals and the broader market conditions. The recent price movement may indicate a shift in investor sentiment, but it is essential to remain vigilant and conduct thorough research before making investment decisions.

References:
[1] https://www.marketbeat.com/instant-alerts/xbiotech-nasdaqxbit-share-price-passes-above-fifty-day-moving-average-whats-next-2025-08-20/